Exiqon A/S has today received the information that Scandinavian Life Science Venture's shareholding in Exiqon A/S via Medicon Valley Capital KB and Medicon Valley Capital K/S now amounts to 0% in connection with the funds' distribution to their investors. See attached pdf-document
Attachments
